Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Xue YZ, Wu TL, Wu YM, Sheng YY, Wei ZQ, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Oct;34(5):2857-61. doi: 10.1007/s13277-013-0846-4. Epub 2013 May 17.

PMID:
23681804
2.

Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.

Zhao L, Cui Q, Lu Z, Chen J.

Pancreas. 2012 Mar;41(2):206-11. doi: 10.1097/MPA.0b013e318223d1a5.

PMID:
21792082
3.

Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.

Zhao ZK, Wu WG, Chen L, Dong P, Gu J, Mu JS, Yang JH, Liu YB.

Tumour Biol. 2013 Jun;34(3):1473-7. doi: 10.1007/s13277-013-0671-9. Epub 2013 Jan 26.

PMID:
23355337
4.

MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.

Chen DW, Fan YF, Li J, Jiang XX.

Tumour Biol. 2013 Jun;34(3):1553-7. doi: 10.1007/s13277-013-0685-3. Epub 2013 Feb 12.

PMID:
23400716
5.

Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.

Lu XX, Zhang SM, Fang Y, Wang ZT, Xie JJ, Zhan Q, Deng XX, Chen H, Jin JB, Peng CH, Li HW, Shen BY.

Tumour Biol. 2013 Dec;34(6):3339-43. doi: 10.1007/s13277-013-0903-z. Epub 2013 Jun 8.

PMID:
23749490
6.

Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.

Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.

World J Gastroenterol. 2015 Aug 21;21(31):9348-57. doi: 10.3748/wjg.v21.i31.9348.

7.

High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.

Wang L, Gu F, Liu CY, Wang RJ, Li J, Xu JY.

Tumour Biol. 2013 Apr;34(2):853-8. doi: 10.1007/s13277-012-0617-7. Epub 2012 Dec 16.

PMID:
23242609
8.

Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Zong M, Meng M, Li L.

Int J Mol Sci. 2011;12(8):4953-63. doi: 10.3390/ijms12084953. Epub 2011 Aug 3.

9.

Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Apr;34(2):895-9. doi: 10.1007/s13277-012-0624-8. Epub 2012 Dec 18.

PMID:
23247867
10.

Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.

Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W.

Pancreas. 2012 May;41(4):629-35. doi: 10.1097/MPA.0b013e31823bcef2.

PMID:
22249132
11.

Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.

Li W, Liu L, Liu D, Jin S, Yang Y, Tang W, Gong L.

Biochem Biophys Res Commun. 2016 Mar 25;472(1):156-62. doi: 10.1016/j.bbrc.2016.02.087. Epub 2016 Feb 23.

PMID:
26915801
12.

Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.

Ning Z, Wang A, Liang J, Liu J, Zhou T, Yan Q, Wang Z.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9. eCollection 2014.

13.

Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma.

Feng X, Ren C, Zhou W, Liu W, Zeng L, Li G, Wang L, Li M, Zhu B, Yao K, Jiang X.

Mol Carcinog. 2014 Nov;53(11):858-70. doi: 10.1002/mc.22044. Epub 2013 Jun 12.

PMID:
23908159
14.

Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.

Liu Q, Chen J, Wang J, Amos C, Killary AM, Sen S, Wei C, Frazier ML.

Mol Carcinog. 2014 Sep;53(9):711-21. doi: 10.1002/mc.22023. Epub 2013 May 9.

15.

Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.

He D, Zhang YW, Zhang NN, Zhou L, Chen JN, Jiang Y, Shao CK.

Med Oncol. 2015 Apr;32(4):92. doi: 10.1007/s12032-015-0525-y. Epub 2015 Feb 27.

PMID:
25720522
16.

Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.

Ye HL, Li DD, Lin Q, Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM, Chen RW, Li ZH, Chen RF.

World J Gastroenterol. 2015 Jun 7;21(21):6621-30. doi: 10.3748/wjg.v21.i21.6621.

17.

Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase.

Al-Zoubi M, Chipitsyna G, Saxena S, Sarosiek K, Gandhi A, Kang CY, Relles D, Andrelsendecki J, Hyslop T, Yeo CJ, Arafat HA.

J Gastrointest Surg. 2014 Feb;18(2):257-68; discussion 268. doi: 10.1007/s11605-013-2370-7. Epub 2013 Oct 4.

PMID:
24091913
18.

Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.

Masugi Y, Yamazaki K, Emoto K, Effendi K, Tsujikawa H, Kitago M, Itano O, Kitagawa Y, Sakamoto M.

Lab Invest. 2015 Mar;95(3):308-19. doi: 10.1038/labinvest.2014.166. Epub 2015 Jan 19.

19.

Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.

Yan TT, Fu XL, Li J, Bian YN, Liu DJ, Hua R, Ren LL, Li CT, Sun YW, Chen HY, Fang JY, Hong J.

Oncotarget. 2015 Nov 10;6(35):37028-42. doi: 10.18632/oncotarget.5939.

20.

Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.

Zhang H, Gao H, Liu C, Kong Y, Wang C, Zhang H.

Diagn Pathol. 2015 Mar 27;10:13. doi: 10.1186/s13000-015-0253-9.

Supplemental Content

Support Center